Roche partners with Chai Discovery to use its AI models across protein drug discovery programmes
Chai says Roche will deploy its models and design platform, anchored by the Chai-3 foundation model, across multiple therapeutic discovery programmes for protein-based medicines.
Why it matters
Roche partnered with Chai Discovery to apply AI protein design to drug discovery programmes, extending the wave of big-pharma deals with structure-prediction startups. Financial terms were not fully detailed in reachable coverage. Watch for disclosed targets, clinical handoffs, and whether Chai models remain exclusive to Roche programmes.
Key facts
- Roche–Chai Discovery partnership
- AI protein design for drug programmes
- Financial terms not fully detailed in reachable coverage